Treatment | Phase | Tumor types | Efficacy | ClinicalTrials.gov Identifier |
---|---|---|---|---|
Talazoparib | III | Advanced and/or metastatic breast cancer with BRCA mutation | PFS: 8.6 months | NCT01945775 |
Niraparib + Pembrolizumab | I/II | Ovarian Cancer/TNBC | ORR: 15.1%/18.2% | NCT02657889 |
Niraparib + Pembrolizumab | II | NSCLC | ORR: 56.3% | NCT03308942 |
Pamiparib + Tislelizumab | I/Ib | TNBC with either known germline or somatic BRCA1/2 mutations or with documented HRD | ORR: 47.4% PFS: 8.4 months | NCT02660034 |
Daratumumab | II | Follicular Lymphoma | ORR: 12.5% PFS: 3.3 months | NCT02413489 |
Isatuximab + Cemiplimab | I/II | Metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung cancer (NSCLC) | lack of efficacy | NCT03367819 |
OT-82 | I | Relapsed or Refractory Lymphoma | No results | NCT03921879 |
ATG−019 | I | Solid Tumor, Non-Hodgkin’s Lymphoma | No results | NCT04281420 |
KPT−9274 | I | Acute Myeloid Leukemia | No results | NCT04914845 |